ARVIND LTD: Q4 EBITDA 3B RUPEES VS 2.45B (YOY) || Q4 EBITDA MARGIN 12% VS 11.1% (YOY)

ARVIND LTD: Q4 CONS NET PROFIT 1.6B RUPEES VS 1.51B (YOY) || Q4 REVENUE 25.53B RUPEES VS 22.2B (YOY)

COCHIN SHIPYARD: Q4 EBITDA 3.1B RUPEES VS 2.53B (YOY) || Q4 EBITDA MARGIN 20.87% VS 15.35% (YOY)

COCHIN SHIPYARD: Q4 SL NET PROFIT 2.76B RUPEES VS 2.85B (YOY); EST 2.85B || Q4 REVENUE 14.8B RUPEES VS 17.5B (YOY)

OMAXE: Q4 CONS NET LOSS 1.9B RUPEES VS LOSS 1.5B (YOY) || Q4 REVENUE 3.5B RUPEES VS 5.4B (YOY)

JUPITER LIFE LINE HOSPITALS: Q4 EBITDA 907M RUPEES VS 782M (YOY) || Q4 EBITDA MARGIN 23.39% VS 23.94% (YOY)

JUPITER LIFE LINE HOSPITALS: Q4 CONS NET PROFIT 506M RUPEES VS 449M (YOY) || Q4 REVENUE 3.9B RUPEES VS 3.3B (YOY)

Mangalam Worldwide To Divide Shares At A 1:10 Ratio

DEEPAK NITRITE: Q4 EBITDA 3.8B RUPEES VS 3.2B (YOY) || Q4 EBITDA MARGIN 17.69% VS 14.5% (YOY)

DEEPAK NITRITE: Q4 CONS NET PROFIT 2.2B RUPEES VS 2B (YOY) || Q4 REVENUE 21.2B RUPEES VS 21.8B (YOY)

CUPID: Q4 EBITDA 463M RUPEES VS 135M (YOY) || Q4 EBITDA MARGIN 38.6% VS 23.81% (YOY)

CUPID: Q4 SL NET PROFIT 362M RUPEES VS 116M (YOY) || Q4 REVENUE 1.2B RUPEES VS 565M (YOY)

AARTI DRUGS: Q4 EBITDA 877M RUPEES VS 933M (YOY) || Q4 EBITDA MARGIN 12.18% VS 13.8% (YOY)

AARTI DRUGS: Q4 CONS NET PROFIT 552M RUPEES VS 629M (YOY) || Q4 REVENUE 7.2B RUPEES VS 6.77B (YOY)

VIP INDUSTRIES: Q4 CONS NET LOSS 1.28B RUPEES VS LOSS 326M (YOY) || Q4 REVENUE 4.4B RUPEES VS 4.9B (YOY)

SYMPHONY: Q4 CONS NET LOSS 2.18B RUPEES VS 790M (YOY) || Q4 REVENUE 3.4B RUPEES VS 4.9B (YOY)

AZAD ENGINEERING: Q4 EBITDA 577M RUPEES VS 454M (YOY) || Q4 EBITDA MARGIN 36.68% VS 36.47% (YOY)